Literature DB >> 33221371

Corneal neovascularization.

Matthew P Nicholas1, Naveen Mysore2.   

Abstract

The optical clarity of the cornea is essential for maintaining good visual acuity. Corneal neovascularization, which is a major cause of vision loss worldwide, leads to corneal opacification and often contributes to a cycle of chronic inflammation. While numerous factors prevent angiogenesis within the cornea, infection, inflammation, hypoxia, trauma, corneal degeneration, and corneal transplantation can all disrupt these homeostatic safeguards to promote neovascularization. Here, we summarize its etiopathogenesis and discuss the molecular biology of angiogenesis within the cornea. We then review the clinical assessment and diagnostic evaluation of corneal neovascularization. Finally, we describe current and emerging therapies.
Copyright © 2020. Published by Elsevier Ltd.

Entities:  

Keywords:  Angiogenesis; Corneal neovascularization; Vascular endothelial growth factor (VEGF)

Mesh:

Substances:

Year:  2020        PMID: 33221371     DOI: 10.1016/j.exer.2020.108363

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  17 in total

1.  miR-340-5p mediates the therapeutic effect of mesenchymal stem cells on corneal neovascularization.

Authors:  Jian Pan; Xu Luo; Shujue Zhao; Jianmin Li; Zipei Jiang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-09-08       Impact factor: 3.535

2.  Promotion of corneal angiogenesis by sensory neuron-derived calcitonin gene-related peptide.

Authors:  Shuyan Zhu; Asmaa Zidan; Kunpeng Pang; Aytan Musayeva; Qianyan Kang; Jia Yin
Journal:  Exp Eye Res       Date:  2022-05-23       Impact factor: 3.770

3.  Preparation and in vitro and in vivo evaluation of an isoliquiritigenin-loaded ophthalmic nanoemulsion for the treatment of corneal neovascularization.

Authors:  Rui Zhang; Jingjing Yang; Qing Luo; Jieran Shi; Haohang Xu; Junjie Zhang
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

4.  Melatonin exerts anti-angiogenic and anti-inflammatory effects in alkali-burned corneas.

Authors:  Jie Meng; Bingying Lin; Siyu Huang; Yangyang Li; Pengsen Wu; Fan Zhang; Yu Ke; Xiangqing Hei; Danping Huang
Journal:  Ann Transl Med       Date:  2022-04

Review 5.  An Update on Novel Ocular Nanosystems with Possible Benefits in the Treatment of Corneal Neovascularization.

Authors:  Chenchen Zhang; Yuan Yin; Jing Zhao; Yanxia Li; Yuanping Wang; Zhaoying Zhang; Lingzhi Niu; Yajuan Zheng
Journal:  Int J Nanomedicine       Date:  2022-10-19

6.  Development of a naringenin microemulsion as a prospective ophthalmic delivery system for the treatment of corneal neovascularization: in vitro and in vivo evaluation.

Authors:  Yu Ma; Jingjing Yang; Yali Zhang; Chunyan Zheng; Zhen Liang; Ping Lu; Fei Song; Yuwei Wang; Junjie Zhang
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

7.  Topical application of TAK1 inhibitor encapsulated by gelatin particle alleviates corneal neovascularization.

Authors:  Jiang-Hui Wang; Ching-Li Tseng; Fan-Li Lin; Jinying Chen; Erh-Hsuan Hsieh; Suraj Lama; Yu-Fan Chuang; Satheesh Kumar; Linxin Zhu; Myra B McGuinness; Jessika Hernandez; Leilei Tu; Peng-Yuan Wang; Guei-Sheung Liu
Journal:  Theranostics       Date:  2022-01-01       Impact factor: 11.556

8.  Establishment of the New Zealand white rabbit animal model of fatty keratopathy associated with corneal neovascularization.

Authors:  Yikui Gao; Cong Li; Xiaoyun Li; Minghong Zhang
Journal:  Open Life Sci       Date:  2021-12-03       Impact factor: 0.938

9.  Amniotic membrane transplantation for infectious keratitis: a systematic review and meta-analysis.

Authors:  Darren Shu Jeng Ting; Christin Henein; Dalia G Said; Harminder S Dua
Journal:  Sci Rep       Date:  2021-06-21       Impact factor: 4.996

Review 10.  Corneal Opacity: Cell Biological Determinants of the Transition From Transparency to Transient Haze to Scarring Fibrosis, and Resolution, After Injury.

Authors:  Steven E Wilson; Lycia Pedral Sampaio; Thomas Michael Shiju; Guilherme S L Hilgert; Rodrigo Carlos de Oliveira
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-01-03       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.